LD50=775mg/kg (Rat, oral); LD50=1690 mg/kg (Mouse, oral). When determining the LD50 in rats and mice, progressive sedation, hypnosis and finally respiratoryfailure were noted as the dosage increased. In dogs, no LD50 could be determined as the higher doses produced an emetic action in 15 to 30 minutes. Some adverse events associated with the drug include nausea, vomiting, drowsiness and CNS side effects such as dizziness, headache, and irritability.
Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous system depression. Metaxalone is associated with few side effects and is available as a 800 mg scored tablet.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Metaxalone. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Metaxalone. |
| Hydrocodone | Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone. |
| Magnesium sulfate | The therapeutic efficacy of Metaxalone can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Metaxalone may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Metaxalone. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Metaxalone. |
| Orphenadrine | Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Metaxalone. |
| Pramipexole | Metaxalone may increase the sedative activities of Pramipexole. |
| Ropinirole | Metaxalone may increase the sedative activities of Ropinirole. |
| Rotigotine | Metaxalone may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Metaxalone. |
| Sodium oxybate | Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Metaxalone. |
| Thalidomide | Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Metaxalone. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Metaxalone. |
| Mirtazapine | Metaxalone may increase the serotonergic activities of Mirtazapine. |
| Ethanol | Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Metaxalone is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Metaxalone is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Metaxalone is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when Metaxalone is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Metaxalone is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Metaxalone is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Metaxalone is combined with Nefazodone. |
| Zimelidine | The risk or severity of adverse effects can be increased when Metaxalone is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Metaxalone is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Metaxalone is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Metaxalone. |
| Seproxetine | The risk or severity of adverse effects can be increased when Metaxalone is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when Metaxalone is combined with Levomilnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when Metaxalone is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Metaxalone is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Metaxalone is combined with Alaproclate. |
| Methylene blue | Metaxalone may increase the serotonergic activities of Methylene blue. |
| Benzatropine | Benzatropine may decrease the excretion rate of Metaxalone which could result in a higher serum level. |
| Disopyramide | Disopyramide may decrease the excretion rate of Metaxalone which could result in a higher serum level. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Metaxalone. |
| Propiomazine | The risk or severity of CNS depression can be increased when Metaxalone is combined with Propiomazine. |
| Propantheline | Metaxalone may decrease the excretion rate of Propantheline which could result in a higher serum level. |
| Dicyclomine | Metaxalone may decrease the excretion rate of Dicyclomine which could result in a higher serum level. |
| Tolterodine | Metaxalone may decrease the excretion rate of Tolterodine which could result in a higher serum level. |
| Flavoxate | Metaxalone may decrease the excretion rate of Flavoxate which could result in a higher serum level. |
| Tiotropium | Metaxalone may decrease the excretion rate of Tiotropium which could result in a higher serum level. |
| Fesoterodine | Metaxalone may decrease the excretion rate of Fesoterodine which could result in a higher serum level. |
| Aclidinium | Metaxalone may decrease the excretion rate of Aclidinium which could result in a higher serum level. |
| Trimebutine | Metaxalone may decrease the excretion rate of Trimebutine which could result in a higher serum level. |
| Imidafenacin | Metaxalone may decrease the excretion rate of Imidafenacin which could result in a higher serum level. |
| Propiverine | Metaxalone may decrease the excretion rate of Propiverine which could result in a higher serum level. |
| Chlorpromazine | The risk or severity of CNS depression can be increased when Chlorpromazine is combined with Metaxalone. |
| Maprotiline | The risk or severity of CNS depression can be increased when Metaxalone is combined with Maprotiline. |
| Promethazine | The risk or severity of CNS depression can be increased when Metaxalone is combined with Promethazine. |
| Quetiapine | The risk or severity of CNS depression can be increased when Metaxalone is combined with Quetiapine. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with Metaxalone. |
| Imipramine | The risk or severity of CNS depression can be increased when Imipramine is combined with Metaxalone. |
| Doxepin | The risk or severity of CNS depression can be increased when Metaxalone is combined with Doxepin. |
| Desipramine | The risk or severity of CNS depression can be increased when Metaxalone is combined with Desipramine. |
| Zopiclone | The risk or severity of adverse effects can be increased when Metaxalone is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Metaxalone. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Metaxalone. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with Metaxalone. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Metaxalone. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with Metaxalone. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Metaxalone. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Metaxalone. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Metaxalone. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Metaxalone. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with Metaxalone. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with Metaxalone. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Metaxalone. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with Metaxalone. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with Metaxalone. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with Metaxalone. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with Metaxalone. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with Metaxalone. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with Metaxalone. |
| Venlafaxine | The risk or severity of serotonin syndrome can be increased when Metaxalone is combined with Venlafaxine. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with Metaxalone. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with Metaxalone. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with Metaxalone. |
| Valproic acid | The risk or severity of CNS depression can be increased when Valproic acid is combined with Metaxalone. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Metaxalone. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Metaxalone. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with Metaxalone. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with Metaxalone. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with Metaxalone. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with Metaxalone. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with Metaxalone. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Metaxalone. |